116632-53-2 Usage
General Description
7-Bromoquinolin-2-amine is a chemical compound with the molecular formula C9H7BrN2. It is a derivative of quinoline, a heterocyclic aromatic organic compound. 7-BROMOQUINOLIN-2-AMINE is mainly used in the pharmaceutical industry as an intermediate for the synthesis of various pharmaceutical drugs. It plays a vital role in the development and production of drugs for the treatment of various diseases and medical conditions. Its unique chemical structure and properties make it a valuable building block for the creation of new drugs and therapeutic agents. Additionally, 7-Bromoquinolin-2-amine is also used in research and development activities in the field of medicinal chemistry and drug discovery. Overall, this chemical compound has significant importance in the pharmaceutical industry and scientific research for its applications in drug synthesis and development.
Check Digit Verification of cas no
The CAS Registry Mumber 116632-53-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,6,6,3 and 2 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 116632-53:
(8*1)+(7*1)+(6*6)+(5*6)+(4*3)+(3*2)+(2*5)+(1*3)=112
112 % 10 = 2
So 116632-53-2 is a valid CAS Registry Number.
InChI:InChI=1/C9H7BrN2/c10-7-3-1-6-2-4-9(11)12-8(6)5-7/h1-5H,(H2,11,12)
116632-53-2Relevant articles and documents
SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5
-
Paragraph 0252, (2020/10/20)
The disclosure is directed to methods of treating disease using compounds of Formula (I).
Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2-Aminoquinoline Inhibitors
Cinelli, Maris A.,Li, Huiying,Chreifi, Georges,Poulos, Thomas L.,Silverman, Richard B.
, p. 3958 - 3978 (2017/05/19)
Neuronal nitric oxide synthase (nNOS) inhibition is a promising strategy to treat neurodegenerative disorders, but the development of nNOS inhibitors is often hindered by poor pharmacokinetics. We previously developed a class of membrane-permeable 2-amino
